SCHEMBL5136123

SCHEMBL5136123

CCCCn1c(CN(Cc2ccc(C)c(F)c2)Cc2cccc3ccccc23)cnc1-c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.38
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
TSHR P16473 2/20 0.35
CYP2C19 P33261 1/20 0.35
HSD11B1 P28845 2/20 0.33
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
SLC2A1 P11166 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.31
ICMT O60725 1/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137856 0.92 C5AR1 (0.39) C5AR1PPARGPPARATSHRCYP2C19
SCHEMBL5137854 0.90 C5AR1 (0.37) C5AR1PPARGPPARAALDH1A1LMNA
SCHEMBL5136502 0.90 C5AR1 (0.38) C5AR1PPARGPPARATSHRCYP2C19
SCHEMBL5136057 0.89 TSHR (0.37) C5AR1PPARGPPARATSHRCYP2C19
SCHEMBL5136850 0.89 TSHR (0.39) C5AR1PPARGPPARATSHRCYP2C19
SCHEMBL5134992 0.88 TSHR (0.41) C5AR1TSHRHSD11B1ALDH1A1LMNA
SCHEMBL5072389 0.88 TSHR (0.41) C5AR1PPARGPPARATSHRCYP2C19
SCHEMBL5134491 0.88 C5AR1 (0.38) C5AR1PPARGPPARATSHRCYP2C19
SCHEMBL5135729 0.88 PPARG (0.40) C5AR1PPARGPPARATSHRCYP2C19
SCHEMBL5137298 0.88 PPARG (0.39) C5AR1PPARGPPARATSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed